Evolus CFO Departs, Interim Appointed; New Directors Elected
Ticker: EOLS · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1570562
Sentiment: neutral
Topics: management-change, board-election, cfo-departure
Related Tickers: EVLS
TL;DR
Evolus CFO out, interim in. Two new board members join.
AI Summary
Evolus, Inc. announced on June 5, 2025, the departure of its Chief Financial Officer, Michael J. MacIntyre, effective June 14, 2025. The company also appointed Dr. David W. R. Hall as interim CFO. Additionally, Evolus reported on the election of two new directors, Dr. David W. R. Hall and Ms. Sarah B. Michelson, to its Board of Directors, effective June 5, 2025.
Why It Matters
This filing indicates significant changes in Evolus's financial leadership and board composition, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key financial and board positions can introduce uncertainty regarding future strategy and financial management.
Key Players & Entities
- Evolus, Inc. (company) — Registrant
- Michael J. MacIntyre (person) — Departing Chief Financial Officer
- June 14, 2025 (date) — Effective date of CFO departure
- David W. R. Hall (person) — Appointed Interim Chief Financial Officer and Director
- Sarah B. Michelson (person) — Elected Director
- June 5, 2025 (date) — Effective date of director election
FAQ
Who is departing as Chief Financial Officer of Evolus, Inc. and when is their departure effective?
Michael J. MacIntyre is departing as Chief Financial Officer, with his departure effective June 14, 2025.
Who has been appointed as the interim Chief Financial Officer for Evolus, Inc.?
Dr. David W. R. Hall has been appointed as the interim Chief Financial Officer.
When were the new directors elected to Evolus, Inc.'s Board of Directors?
The new directors were elected effective June 5, 2025.
Who are the newly elected directors of Evolus, Inc.?
The newly elected directors are Dr. David W. R. Hall and Ms. Sarah B. Michelson.
What is the primary business of Evolus, Inc. according to the filing?
Evolus, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 by Michael J. MacIntyre regarding Evolus, Inc. (EOLS).